Research & Reviews: Drug Delivery

Metabolism of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and their Side Effects

Kattab Omar*

Department of Pharmacy, New York University, New York, United States of America

Short Communication

Received: 26-Nov-2024, Manuscript No. DD-24-156806; **Editor assigned:** 28-Nov-2024, PreQC No. DD-24-156806 (PQ); **Reviewed:** 11-Dec-2024, QC No. DD-24-156806; **Revised:** 18-Dec-2024, Manuscript No. DD-24-156806 (R); **Published:** 25-Dec-2024, DOI:10.4172/resrevdrugdeliv.8.4.005

***For Correspondence:**
Kattab Omar, Department of Pharmacy, New York University, New York, United States of America
E-mail: knom443568@hotmail.com

Citation: Omar K. Metabolism of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and their Side Effects. Res Rev Drug Deliv. 2024;8:005.

ABOUT THE STUDY

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are among the most commonly used medications worldwide for the treatment of pain, inflammation and fever. They are utilized in a wide range of conditions, including arthritis, musculoskeletal disorders and post-operative pain management. While NSAIDs are effective in providing relief, their metabolism and associated side effects require careful consideration.

Metabolism of NSAIDs

The metabolism of NSAIDs is primarily mediated through the liver, where they undergo phase I and phase II metabolic processes. The cytochrome P450 (*CYP450*) enzyme system, which consists of a large family of enzymes, plays an important role in the oxidative metabolism of most NSAIDs. These enzymes are responsible for the conversion of NSAIDs into more water-soluble metabolites, which can be easily excreted in the urine.

The metabolism of NSAIDs is generally influenced by several factors, including the specific drug, its formulation, genetic variations in metabolic enzymes and the presence of other drugs that may inhibit or induce these enzymes. For instance, drugs like ibuprofen and naproxen are metabolized mainly by *CYP2C9*, while others, such as celecoxib, are metabolized by *CYP2C9* and *CYP3A4*. The influence of genetic polymorphisms in these enzymes may lead to variability in the metabolism of NSAIDs between individuals, affecting drug efficacy and toxicity. Once metabolized, NSAIDs are typically excreted through the kidneys, although a small amount may be eliminated through bile.

The excretion of NSAIDs is influenced by factors such as renal function, hydration status and the presence of other medications that may affect renal clearance. In individuals with impaired renal function, NSAIDs may accumulate to higher concentrations, increasing the risk of toxicity [1-4].

Common NSAID side effects

Despite their widespread use, NSAIDs are associated with a range of side effects, which can vary in severity. These adverse effects are mainly related to their mechanism of action, which involves the inhibition of cyclooxygenase (COX) enzymes. COX enzymes are responsible for the production of prostaglandins, which mediate inflammation, pain and fever. While the inhibition of COX-1 is associated with therapeutic effects, it also leads to unwanted side effects, particularly on the Gastrointestinal (GI) system, kidneys and cardiovascular health [5-8].

One of the most significant adverse effects of NSAIDs is gastrointestinal toxicity. The inhibition of COX-1 reduces the protective prostaglandins that maintain the integrity of the gastric mucosa, making it more susceptible to ulceration and bleeding. Long-term or high-dose NSAID use can result in peptic ulcers, gastrointestinal bleeding, and even perforation. These risks are higher in elderly individuals and those with a history of gastrointestinal disorders.

NSAIDs can also affect renal function, particularly in individuals with preexisting kidney disease or those who are dehydrated. COX inhibition leads to reduced prostaglandin synthesis, which can impair renal blood flow, particularly in the glomerulus. This can result in Acute Kidney Injury (AKI), especially when NSAIDs are used in conjunction with other nephrotoxic drugs or in patients with conditions such as heart failure or cirrhosis. Chronic use of NSAIDs has been linked to the development of Chronic Kidney Disease (CKD), highlighting the importance of monitoring renal function during long-term NSAID therapy.

In recent years, the cardiovascular risks associated with NSAIDs have gained attention, particularly with drugs that selectively inhibit COX-2, such as celecoxib. While COX-2 inhibitors are designed to reduce the gastrointestinal side effects of traditional NSAIDs, they may increase the risk of cardiovascular events, including heart attack, stroke and hypertension. This is due to the imbalance created by inhibiting COX-2, which leads to decreased production of prostacyclin, a compound that has protective effects on the cardiovascular system. The risk is particularly high in individuals with pre-existing cardiovascular disease or risk factors such as hypertension, diabetes and smoking [9,10].

Hepatic Toxicity: Although less common, liver toxicity is a potential side effect of NSAIDs. The liver is responsible for the metabolism of many NSAIDs and in rare cases, these drugs can cause liver damage, ranging from mild elevation in liver enzymes to acute liver failure. Monitoring liver function during NSAID therapy is recommended, particularly in patients with pre-existing liver disease.

Hypersensitivity reactions

Some individuals may develop hypersensitivity reactions to NSAIDs, including rashes, bronchospasm and anaphylaxis. This is particularly common in patients with asthma, as NSAIDs can trigger bronchoconstriction in these individuals due to their effect on leukotriene pathways.

While NSAIDs are effective in managing pain and inflammation, their metabolism and potential side effects must be carefully considered. The inhibition of COX enzymes, particularly COX-1, underlies many of the common adverse effects, including gastrointestinal, renal, cardiovascular and hepatic toxicity. Understanding the metabolic pathways of NSAIDs, as well as patient-specific factors such as genetic variations, renal function and coexisting health conditions, is essential in minimizing the risks associated with these drugs. Patients using NSAIDs should be

monitored regularly, especially those on long-term therapy or with pre-existing conditions, to ensure the safe and effective use of these medications.

REFERENCES

1. Abouhussein DM. Enhanced transdermal permeation of BCS class IV aprepitant using binary ethosome: Optimization, characterization and *ex-vivo* permeation. J Drug Deliv Sci Technol. 2021;61:102185.
2. Ali M, et al. Dissolvable polymer microneedles for drug delivery and diagnostics. J Control Release. 2022 ;347:561–589.
3. Apolinário AC, et al. Design of multifunctional ethosomes for topical fenretinide delivery and breast cancer chemoprevention. Colloids Surfaces A Physicochem Eng Aspects. 2021;623:126745.
4. Avcil M, et al. Microneedles in drug delivery: Progress and challenges. Micromachines. 2021;12:1321.
5. Benson HA, et al. Topical and transdermal drug delivery: From simple potions to smart technologies. Curr Drug Deliv. 2019;16:444–460.
6. Bieber T. Atopic dermatitis: An expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2021;21:21–40.
7. Bruce J, et al. Parenteral drug administration errors by nursing staff on an acute medical admissions ward during day duty. Drug-Safety, 2001;24:855-862.
8. Kydonieus AF, et al. Biochemical modulation of skin reactions: Transdermals, topicals, cosmetics. CRC Press. 1999.
9. Bruno BJ, et al. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4:1443-1467.
10. Hua S. Physiological and pharmaceutical considerations for rectal drug formulations. Front Pharmacol. 2019;10:1196.